Firm says that the molecules have promise against CNS-related indications.
Evotec confirmed a potentially €1.5 million (about $1.99 million) grant from the German Federal Ministry of Education and Research (BMBF) to fund its H3 receptor antagonist through Phase I trials. The company says that its optimized antagonists to the H3 receptor could have the potential to treat a range of CNS indications including excess fatigue associated with multiple sclerosis.
The funding was awarded as a result of Evotec’s involvement in the Neu2 consortium, a German government-funded industry-academia collaboration within the BioPharma initiative, which aims to develop new therapeutics against MS and other neurodegenerative diseases.
“We are happy that the Neu2 consortium has chosen to support our H3 receptor antagonist program for further development within the BioPharma initiative,” states Werner Lanthaler, Ph.D., Evotec CEO. “By driving these novel drug candidates from identification through to the first clinical steps, we can optimally capture the commercial value of this program.”
